INmune Bio (NASDAQ:INMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of INmune Bio (NASDAQ:INMB) from a sell rating to a hold rating in a report issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

INmune Bio Trading Down 1.0%

INMB stock opened at $1.89 on Friday. INmune Bio has a 1-year low of $1.38 and a 1-year high of $11.64. The stock has a market cap of $50.24 million, a P/E ratio of -0.89 and a beta of 0.91. The stock’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $2.79.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.07. As a group, analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On INmune Bio

Several large investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in INmune Bio in the 3rd quarter worth approximately $30,000. Cary Street Partners Financial LLC purchased a new stake in shares of INmune Bio during the third quarter worth $29,000. Vanguard Group Inc. boosted its holdings in shares of INmune Bio by 3.4% in the third quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock worth $1,814,000 after acquiring an additional 28,541 shares during the period. Westside Investment Management Inc. grew its position in shares of INmune Bio by 384.0% in the third quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after purchasing an additional 82,075 shares in the last quarter. Finally, Independent Advisor Alliance purchased a new position in shares of INmune Bio in the third quarter valued at $30,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.